surmount-1 trial tirzepatide obesity without diabetes weight loss for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Tirzepatide vs. Semaglutide for Weight

Acute pancreatitis In January 2026, the UK MHRA has instructed manufacturers to update the product information for all GLP-1 and dual GIP/GLP-1 receptor agonists to highlight the potential risk of severe acute pancreatitis associated with these drugs, including rare reports of necrotizing and fatal pancreatitis [13]

YOU CAN CHECK IF A COMPOUNDING PHARMACY IS ACCREDITED HERE: AND MORE INFORMATION ABOUT COMPOUNDING PHARMACIES HERE: 2025 Richard Weil, M.Ed., CDE, All Rights Reserved

The biotin-ligating protein BPL-1 is critical for lipid biosynthesis and polarization of the Caenorhabditis elegans embryo

PMID: 33946883